Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

Italian Real-world Study on Epcoritamab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy

Inclusion Criteria:

• Age ≥ 18 years
• Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024)
• Received at least one dose of epcoritamab
• Free and voluntary written informed consent

Exclusion Criteria:

• Age < 18 years
• Patients who received epcoritamab outside the Cnn program (e.g., open access program, compassionate use, off-label, prospective trials).